

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	716	febrifugine or halofuginone or isofebrifugine	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/07/19 13:30
L2	1111	"protozoan infection"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/07/19 13:31
L3	6	L1 and L2	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/07/19 13:31

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXX

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	3	MAR 16	CASREACT coverage extended
NEWS	4	MAR 20	MARPAT now updated daily
NEWS	5	MAR 22	LWPI reloaded
NEWS	6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	10	APR 30	CA/CAPplus enhanced with 1870-1889 U.S. patent records
NEWS	11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	12	MAY 01	New CAS web site launched
NEWS	13	MAY 08	CA/CAPplus Indian patent publication number format defined
NEWS	14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	17	MAY 21	CA/CAPplus enhanced with additional kind codes for German patents
NEWS	18	MAY 22	CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS	19	JUN 27	CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS	20	JUN 29	STN Viewer now available
NEWS	21	JUN 29	STN Express, Version 8.2, now available
NEWS	22	JUL 02	LEMBASE coverage updated
NEWS	23	JUL 02	LMEDLINE coverage updated
NEWS	24	JUL 02	SCISEARCH enhanced with complete author names
NEWS	25	JUL 02	CHEMCATS accession numbers revised
NEWS	26	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	27	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	28	JUL 18	CA/CAPplus patent coverage enhanced
NEWS EXPRESS	29	JUNE 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN. Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:33:52 ON 19 JUL 2007

=> file caplus medline biosis embase

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 13:34:30 ON 19 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:34:30 ON 19 JUL 2007

FILE 'BIOSIS' ENTERED AT 13:34:30 ON 19 JUL 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:34:30 ON 19 JUL 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

=> s febrifugine

L1 229 FEBRIFUGINE

=> s halofuginone

L2 1096 HALOFUGINONE

=> s protozoan infection

L3 5560 PROTOZOAN INFECTION

=> dup rem L1

PROCESSING COMPLETED FOR L1

L4 139 DUP REM L1 (90 DUPLICATES REMOVED)

=> s L4 and (AY<2003 or PY<2003 or PRY<2003)

'2003' NOT A VALID FIELD CODE

'2003' NOT A VALID FIELD CODE

2 FILES SEARCHED...

'2003' NOT A VALID FIELD CODE

'2003' NOT A VALID FIELD CODE

'2003' NOT A VALID FIELD CODE

'2003' NOT A VALID FIELD CODE

L5 101 L4 AND (AY<2003 OR PY<2003 OR PRY<2003)

=> s L5 and L3

L6 0 L5 AND L3

=> s L5 and infections

L7 4 L5 AND INFECTIONS

=> d 1-4 ibib abs

L7 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:21603 CAPLUS

DOCUMENT NUMBER: 132:73628

TITLE: Febrifugine derivatives having antimalarial activity

INVENTOR(S): Oshima, Yoshiteru; Takaya, Yoshiaki; Wataya, Yusuke

PATENT ASSIGNEE(S): Taiho Pharmaceutical Co., Ltd., Japan


SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000007673	A	20000111	JP 1998-172578	19980619 <--
JP 3740284	B2	20060201		
PRIORITY APPLN. INFO.:			JP 1998-172578	19980619 <--
OTHER SOURCE(S):	MARPAT 132:73628			
GI				



I

AB Febrifugine or isofebrifugine derivs. I (R1, R2 = H, hydrocarbon; either R3 or R4 is H and the other is OH or OAc; CR3R4 may form C:O; R5 = acyl, selectively releasable ether-type protective group) or their salts are useful for prevention and treatment of malarial infections. Febrifugine extracted from *Dichroa febrifuga* was stirred in Me2CO in the presence of silica gel to give acetonylfebrifugine, which inhibited *Plasmodium falciparum* with EC50 of 3.2 + 10-10 M.

L7 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1950:31220 CAPLUS  
 DOCUMENT NUMBER: 44:31220  
 ORIGINAL REFERENCE NO.: 44:6086d-h  
 TITLE: Obtaining febrifugine alkaloids  
 INVENTOR(S): Koepfli, Joseph B.; Mead, James F.; Brockman, John A., Jr.  
 PATENT ASSIGNEE(S): United States of America, as represented by the Secy. of the Army  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2504847		19500418	US 1948-26428	19480511 <--

AB Ground roots of *Dichroa febrifuga* are extracted repeatedly with 0.1 N HCl for 48 hrs. and are soaked until test with Dragendorff's reagent is neg. The alkaloids are adsorbed on fuller's earth (amount calculated from a graph) with excess HCl and long stirring, and filtered. The filter cake is made into a thin paste with H2O, Na2CO3 is added to pH 8.5 or higher, BuOH (3 times amount of H2O) is added, and the mixture is shaken for 1-3 hrs. The extraction with BuOH is repeated, 0.5 volume ligroin (b. 60-70°) and 0.5 volume % 6 N HCl are added to the BuOH, the aqueous layer is separated, the BuOH is extracted with 0.1 N HCl, the combined aqueous exts. are neutralized with Na2CO3, extracted

with 20 volume % BuOH in CHCl<sub>3</sub>, this is extracted with 0.25 N HCl, and the neutralization-extraction cycle is repeated. The final BuOH-CHCl<sub>3</sub> is evaporated, and the residue is collected by use of Et<sub>2</sub>O, crystallized from EtOH and excess 12 N HCl, and recrystd. by dissolving in 50% EtOH and adding absolute EtOH to 90% to give febrifugine-2HCl: free base (I) m. 152-4° (from CHCl<sub>3</sub>) and 139-40° (from EtOH). Filtrates from I-2HCl are evaporated, and H<sub>2</sub>O and Na<sub>2</sub>CO<sub>3</sub> are added and extracted with CHCl<sub>3</sub> to give isofebrifugine (II), recrystd. rapidly from hot MeOH. II heated at m. p. or refluxed in EtOH is partially converted to I; similarly some II is obtained from I in hot CHCl<sub>3</sub>. The roots contain 0.05-0.10% alkaloid and far more I than II. For more phys. data see abstract from J. Am. Chemical Society in C.A. 41, 5984a. I has LD<sub>50</sub> of 2.5-3.0 mg./kg. in the white mouse and has delayed toxic manifestations. In rhesus monkeys I is more than 300 times as toxic (subacute) than quinine, causes loss of weight at doses of 0.6 mg./kg. daily, and is 50 times as active as quinine against Plasmodium cynomolgi infections.

L7 ANSWER 3 OF 4 MEDLINE on STN  
 ACCESSION NUMBER: 75157215 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 1128923  
 TITLE: Laboratory studies with some recent anticoccidials.  
 AUTHOR: Ryley J F; Wilson R G  
 SOURCE: Parasitology, (1975 Apr) Vol. 70, No. 2, pp. 203-22.  
 Journal code: 0401121. ISSN: 0031-1820.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 197508  
 ENTRY DATE: Entered STN: 10 Mar 1990  
 Last Updated on STN: 10 Mar 1990  
 Entered Medline: 8 Aug 1975

AB The activities of monensin, lasalocid and halofuginone against Eimeria tenella, E. brunetti and E. necatrix have been studied under laboratory conditions. Complete control of experimental infections in the chick, separable from toxicity, was not obtained with monensin, but was achieved with the other two compounds at levels of 150 and 6 ppm in the food respectively. All three compounds appear to inhibit coccidial development very early in the life-cycle, and to have a fairly rapid lethal effect, monensin and lasalocid more so than the febrifugine derivative. In vivo observations have been supplemented with in vitro studies. Some discussion of the difficulties of relating laboratory experiments to field performance is given.

L7 ANSWER 4 OF 4 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN  
 ACCESSION NUMBER: 89169326 EMBASE  
 DOCUMENT NUMBER: 1989169326  
 TITLE: New leads to the treatment of protozoal infections based on natural product molecules.  
 AUTHOR: Phillipson J.D.; O'Neill M.J.  
 CORPORATE SOURCE: Department of Pharmacognosy, The School of Pharmacy, University of London, London WC1N 1AX, United Kingdom  
 SOURCE: Acta Pharmaceutica Nordica, (1989) Vol. 1, No. 3, pp. 131-144.  
 ISSN: 1100-1801 CODEN: APNOEE  
 COUNTRY: Sweden  
 DOCUMENT TYPE: Journal  
 FILE SEGMENT: 037 Drug Literature Index  
 LANGUAGE: English  
 ENTRY DATE: Entered STN: 12 Dec 1991  
 Last Updated on STN: 12 Dec 1991

DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

=> s L2 and infections  
L8 85 L2 AND INFECTIONS

=> dup rem L8  
PROCESSING COMPLETED FOR L8  
L9 48 DUP REM L8 (37 DUPLICATES REMOVED)

=> s L9 and (AY<2003 or PY<2003 or PRY<2003)  
'2003' NOT A VALID FIELD CODE  
'2003' NOT A VALID FIELD CODE  
2 FILES SEARCHED...  
'2003' NOT A VALID FIELD CODE  
'2003' NOT A VALID FIELD CODE  
'2003' NOT A VALID FIELD CODE  
'2003' NOT A VALID FIELD CODE  
L10 41 L9 AND (AY<2003 OR PY<2003 OR PRY<2003)

=> s protozoal or protozoan  
L11 323012 PROTOZOAL OR PROTOZOAN

=> s L10 and L11  
L12 11 L10 AND L11

=> d 1-11 L12 ibib abs

L12 ANSWER 1 OF 11 MEDLINE on STN  
ACCESSION NUMBER: 90320070 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 2115212  
TITLE: Elimination of Theileria buffeli infections from  
cattle by concurrent treatment with primaquine phosphate  
and halofuginone lactate.  
AUTHOR: Stewart N P; de Vos A J; Shiels I  
CORPORATE SOURCE: Queensland Department of Primary Industries, Animal  
Research Institute, Wacol, Queensland, Australia.  
SOURCE: Tropical animal health and production, (1990 May)  
Vol. 22, No. 2, pp. 109-15.  
Journal code: 1277355. ISSN: 0049-4747.  
PUB. COUNTRY: SCOTLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199008  
ENTRY DATE: Entered STN: 21 Sep 1990  
Last Updated on STN: 21 Sep 1990  
Entered Medline: 21 Aug 1990

AB Fifty splenectomised calves naturally infected with Theileria buffeli were treated with primaquine phosphate (ICI, UK) and halofuginone lactate (Hoechst, Australia) either separately or in combination. Infections in treated calves were monitored for up to 26 weeks by examining Giemsa stained peripheral blood films for piroplasms and by an immunofluorescent antibody test. When used alone neither of the drugs eliminated infection. The most successful results were obtained when two treatments of halofuginone lactate, at a rate of 1 mg kg<sup>-1</sup> body weight and six treatments of primaquine phosphate, at a rate of 2 mg kg<sup>-1</sup> body weight, were administered concurrently. No theilerial relapses were observed in 14 of 16 calves so treated, and no antibody to T. buffeli was detected in these calves beyond the twelfth week after treatment. The results have application in the preparation of Theileria-free calves for use in the production of living vaccines against babesiosis and anaplasmosis.

L12 ANSWER 2 OF 11 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN  
ACCESSION NUMBER: 1986:277331 BIOSIS  
DOCUMENT NUMBER: PREV198682021194; BA82:21194  
TITLE: ASSESSMENT OF ANTICOCCIDIALS AGAINST INTESTINAL EIMERIA IN  
GALLUS-GALLUS-F-DOMESTICA.  
AUTHOR(S): GOMEZ E [Reprint author]; BLANDINO T  
CORPORATE SOURCE: DEP PARASITOL-MICOL, CENT NAC SANIDAD AGROPECUARIA, SAN  
JOSE DE LAS LAJAS, LA HABANA  
SOURCE: Revista de Salud Animal, (1985) Vol. 7, No. 3,  
pp. 275-280.  
CODEN: RSANDH. ISSN: 0253-570X.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BA  
LANGUAGE: SPANISH  
ENTRY DATE: Entered STN: 4 Jul 1986  
Last Updated on STN: 4 Jul 1986

AB The activity of amprolium (125 and 240 ppm), halofuginone (3  
ppm), monensin (100 ppm), salinomycin (60 ppm) and sulphadimidine (2000  
ppm) against experimental mixed infections of fowl intestinal  
coccidia was assessed. Criteria for effectiveness comprised weight gain,  
number of discharged oocysts and alterations in feces. Amprolium (240  
ppm), halofuginone and sulphadimidine showed moderate  
anticoccidial effect according to the described conditions.

L12 ANSWER 3 OF 11 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN  
ACCESSION NUMBER: 1985:164831 BIOSIS  
DOCUMENT NUMBER: PREV198529054827; BR29:54827  
TITLE: IMPLICATIONS OF CHEMOTHERAPY OF THEILERIA-LAWRENCEI  
INFECTIONS CORRIDOR DISEASE IN CATTLE.  
AUTHOR(S): POTGIETER F T [Reprint author]; ROOS J A; DE VOS A J  
CORPORATE SOURCE: VET RES INST, PO BOX ONDERSTEEPOORT 0110  
SOURCE: South African Journal of Science, (1985) Vol. 81,  
No. 1, pp. 44.  
Meeting Info.: ANNUAL MEETING OF THE PARASITOLOGICAL  
SOCIETY OF SOUTHERN AFRICA, JOHANNESBURG, SOUTH AFRICA,  
JUNE 28-29, 1984. S AFR J SCI.  
CODEN: SAJSAR. ISSN: 0038-2353.  
DOCUMENT TYPE: Conference; (Meeting)  
FILE SEGMENT: BR  
LANGUAGE: ENGLISH

L12 ANSWER 4 OF 11 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN  
ACCESSION NUMBER: 1981:138321 BIOSIS  
DOCUMENT NUMBER: PREV198171008313; BA71:8313  
TITLE: THE ANTI COCCIDIAL EFFICACY OF ARPRINOCID IN BROILER  
CHICKENS UNDER FLOOR PEN CONDITIONS.  
AUTHOR(S): SCHROEDER J [Reprint author]; SMITH C J Z; HARVEY R G  
CORPORATE SOURCE: MSD RES CENT, PRIV BAG 3, 1685 HALFWAY HOUSE, S AFR  
SOURCE: Journal of the South African Veterinary Association, (1980) Vol. 51, No. 1, pp. 59-61.  
CODEN: JAVTAP. ISSN: 0038-2809.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BA  
LANGUAGE: ENGLISH

AB The efficacy of arprinocid was tested against artificial  
infections of mixtures of Eimeria spp. in broiler chickens under  
floor pen conditions in 3 experiments. Treatment with arprinocid at 60  
ppm over 56 days significantly increased the live mass gain and feed  
efficiency of broiler chickens. This increase compared favorably with  
that obtained by treatment with lasalocid, robenidine and  
halofuginone. Birds treated with arprinocid had substantially  
reduced numbers of sporulated oocysts in their litter, and less severe  
lesion scores than non-mediated birds.

L12 ANSWER 5 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002078501 EMBASE  
TITLE: Parasites of goats: A guide to diagnosis and control.  
AUTHOR: Taylor M.  
SOURCE: In Practice, (2002) Vol. 24, No. 2, pp. 76-89. .  
ISSN: 0263-841X CODEN: IPRCDH  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 004 Microbiology  
030 Pharmacology  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 14 Mar 2002  
Last Updated on STN: 14 Mar 2002

AB Goats share a number of diseases in common with sheep and cattle and this is particularly true with regard to parasitic infections. The most important endoparasitic diseases seen in goats are parasitic gastroenteritis caused by gastrointestinal nematodes, and coccidiosis caused by protozoan parasites of the genus Eimeria. Other internal parasitic infections seen in goats include cryptosporidiosis, a rapidly emerging zoonotic infection of domestic animals (and humans), adult tapeworms and several metacestodes, and insect larvae of the family Oestridae (bots and warbles). Ectoparasites may be found either permanently on goats (eg, mites and lice) or only when they come to feed (eg, ticks and flies). Such parasites may be a source of annoyance or may result in illthrift and disease. This article discusses the pathogenesis, diagnosis and control of the major endo- and ectoparasitic infections of goats.

L12 ANSWER 6 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001368223 EMBASE  
TITLE: Chemotherapeutic approaches to protozoa: Coccidia - Current level of knowledge and outlook.  
AUTHOR: Greif G.; Harder A.; Haberkorn A.  
CORPORATE SOURCE: G. Greif, Animal Health Business Group, Research and Development, Biological and Chemical Evaluation, 51368 Leverkusen, Germany. gisela.greif.ah@bayer.ag.de  
SOURCE: Parasitology Research, (2001) Vol. 87, No. 11, pp. 973-975.  
Refs: 4  
ISSN: 0932-0113 CODEN: PARREZ  
COUNTRY: Germany  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 004 Microbiology  
030 Pharmacology  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 2 Nov 2001  
Last Updated on STN: 2 Nov 2001

AB Progress in the treatment and prophylaxis of cystforming coccidial infections (Neospora, Sarcocystis, Toxoplasma) and Cryptosporidium infections has been limited (Table 1; Haberkorn 1996; Croft 1997; Wang 1997). However, new possibilities have been opened up in the treatment of Eimeria-induced coccidiosis in poultry and mammals, due to improvements in treatment and/or metaphylaxis. A new polyether antibiotic, semduramycin, has recently been added to the range of effective prophylactic preparations. The development of resistance to anticoccidial agents is now posing similar problems to those encountered with malaria, coccidiosis in poultry being particularly affected. Because no new active ingredient from a new family of chemical substances has been



developed for more than 10 years, the following approaches are being adopted to get round this problem: the use of older preparations which have not been used for a long time, the introduction of combinations such as narasin/nicarbazin or methyl benzoquate/clopidol and the alternating use of anticoccidial agents in rotation and shuttle programmes. The goal of a real alternative, i.e. vaccination, has been achieved to a certain extent in the form of live vaccines for laying hens and broiler breeders and is being practiced in some countries.

L12 ANSWER 7 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1998333813 EMBASE  
TITLE: [Cryptosporidium infections in immunocompetent and immunocompromised host].  
L'INFEZIONE DA CRIPTOSPORIDIO NELL'OSPITE IMMUNOCOMPETENTE E NEL PAZIENTE IMMUNOCOMPROMESSO.  
AUTHOR: Maisto A.; Sorrentino A.R.; Gaeta G.B.  
CORPORATE SOURCE: A. Maisto, Istituto di Malattie Infettive, Seconda Università, Napoli, Italy  
SOURCE: Infezioni in Medicina, (1998) Vol. 6, No. 3, pp. 139-147. .  
Refs: 111  
ISSN: 1124-9390 CODEN: INMEFK  
COUNTRY: Italy  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 004 Microbiology  
006 Internal Medicine  
017 Public Health, Social Medicine and Epidemiology  
026 Immunology, Serology and Transplantation  
037 Drug Literature Index  
LANGUAGE: Italian  
SUMMARY LANGUAGE: English; Italian  
ENTRY DATE: Entered STN: 28 Oct 1998  
Last Updated on STN: 28 Oct 1998

AB Prior to 1980 infections with Cryptosporidium species were considered extremely rare in humans. During the eighties, evidence cumulates that this intracellular protozoan was often responsible of self-limiting diarrheal illness in immunocompetent patients and of a prolonged, life-threatening disease in immunocompromised hosts, especially patients with AIDS. The aim of this paper is to review the present knowledge on Cryptosporidium biology, epidemiology, pathogenesis, diagnosis, therapy and highlight recent studies on the clinical aspects of this infection.

L12 ANSWER 8 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 93113989 EMBASE  
DOCUMENT NUMBER: 1993113989  
TITLE: Opportunistic infections: Treatment and developmental therapeutics of cryptosporidiosis and isosporiasis.  
AUTHOR: St. Georgiev V.  
CORPORATE SOURCE: Nat. Inst. Allergy/Infectious Dis., National Institutes of Health, Solar Building, Bethesda, MD 20892, United States  
SOURCE: Drug Development Research, (1993) Vol. 28, No. 4, pp. 445-459. .  
ISSN: 0272-4391 CODEN: DDREDK  
COUNTRY: United States  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 004 Microbiology  
030 Pharmacology  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 30 May 1993

Last Updated on STN: 30 May 1993

AB Cryptosporidium sp. and Isospora sp. are coccidian protozoans taxonomically related to Toxoplasma gondii and Plasmodium sp. Although associated with many animal species, these pathogens are also the causative agents of cryptosporidiosis and isosporiasis, 2 invasive opportunistic infections in humans. In immunocompetent hosts, the infections are usually self-limited, flu-like gastrointestinal disorders which resolve spontaneously. In immunocompromised patients, however, cryptosporidiosis is a severe, debilitating, and prolonged illness, with high morbidity and no known therapy effective against it. Spiramycin has been proven largely ineffective. In recent years, however, the use of immunotherapy is being actively pursued as one potentially useful approach for the treatment of cryptosporidiosis. Azithromycin, a new macrolide antibiotic, has also shown promise in preclinical studies. In the case of isosporiasis, the combination of trimethoprim and sulphamethoxazole has been found to be effective, although AIDS patients have shown a high rate of relapse and, therefore, the need for suppressive maintenance therapy.

L12 ANSWER 9 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 92069393 EMBASE  
DOCUMENT NUMBER: 1992069393  
TITLE: Protozoal gastrointestinal infections.  
AUTHOR: Hamer D.H.; Keusch G.T.  
CORPORATE SOURCE: New England Medical Center Hospitals-Tufts University School of Medicine, Department of Medicine, Division of Geographic Medicine and Infectious Diseases, 750 Washington Street, NEMCH 341 Boston, MA 02111, United States  
SOURCE: Current Opinion in Infectious Diseases, (1992) Vol. 5, No. 1, pp. 88-98. .  
ISSN: 0951-7375 CODEN: COIDE5  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 004 Microbiology  
037 Drug Literature Index  
048 Gastroenterology  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 29 Mar 1992  
Last Updated on STN: 29 Mar 1992

DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L12 ANSWER 10 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 92019139 EMBASE  
DOCUMENT NUMBER: 1992019139  
TITLE: Therapy for enteric protozoa.  
AUTHOR: Janoff E.N.  
CORPORATE SOURCE: VA Medical Center, Infectious Disease Section (111F), One Veterans Drive, Minneapolis, MN 55417, United States  
SOURCE: Current Opinion in Infectious Diseases, (1991) Vol. 4, No. 6, pp. 820-825. .  
ISSN: 0951-7375 CODEN: COIDE5  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 004 Microbiology  
006 Internal Medicine  
037 Drug Literature Index  
048 Gastroenterology  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 20 Mar 1992  
Last Updated on STN: 20 Mar 1992

AB Enteric protozoa are common, identifiable, and often treatable causes of enteric disease in children and adults worldwide. In the last decade, use of newer diagnostic methods and the rapid growth of the population of immunocompromised patients has led to an expanded list of potential protozoan pathogens. Prominent among these pathogens are Cryptosporidium and Microsporidium organisms, both of which are associated with chronic diarrheal disease in patients with human immunodeficiency virus infection and for which effective therapy is not yet available. The challenge for the next decade is to establish reliable and accessible diagnostic techniques for identifying new enteric protozoan infections and to establish safe and effective therapeutic regimens.

L12 ANSWER 11 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 81201226 EMBASE

DOCUMENT NUMBER: 1981201226

TITLE: The chemotherapy of protozoal infections of veterinary importance.

AUTHOR: Joyner L.P.

CORPORATE SOURCE: Parasitol. Dept., Cent. Veter. Lab., Min. Agric. Fisheries Food, Weybridge, United Kingdom

SOURCE: Journal of Protozoology, (1981) Vol. 28, No. 1, pp. 17-19.

CODEN: JPROAR

COUNTRY: United States

DOCUMENT TYPE: Journal

FILE SEGMENT: 037 Drug Literature Index

LANGUAGE: English

ENTRY DATE: Entered STN: 9 Dec 1991

Last Updated on STN: 9 Dec 1991

DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER